Technical Analysis for ELVN - Enliven Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Outside Day | Range Expansion | 0.54% | |
Wide Bands | Range Expansion | 0.54% | |
Overbought Stochastic | Strength | 0.54% | |
NR7 | Range Contraction | -2.00% | |
Narrow Range Bar | Range Contraction | -2.00% | |
Wide Bands | Range Expansion | -2.00% | |
Gapped Up | Strength | -2.00% |
Alert | Time |
---|---|
10 DMA Support | about 16 hours ago |
Gap Up Closed | about 17 hours ago |
2x Volume Pace | about 17 hours ago |
1.5x Volume Pace | about 17 hours ago |
Fell Below Previous Day's Low | about 17 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Her2 Chronic Myeloid Leukemia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Her2 Chronic Myeloid Leukemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 26.0 |
52 Week Low | 9.84 |
Average Volume | 359,953 |
200-Day Moving Average | 15.31 |
50-Day Moving Average | 18.56 |
20-Day Moving Average | 20.51 |
10-Day Moving Average | 23.54 |
Average True Range | 1.58 |
RSI (14) | 64.41 |
ADX | 28.21 |
+DI | 32.07 |
-DI | 14.67 |
Chandelier Exit (Long, 3 ATRs) | 20.41 |
Chandelier Exit (Short, 3 ATRs) | 20.71 |
Upper Bollinger Bands | 26.78 |
Lower Bollinger Band | 14.23 |
Percent B (%b) | 0.78 |
BandWidth | 61.24 |
MACD Line | 1.70 |
MACD Signal Line | 1.35 |
MACD Histogram | 0.3461 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 25.94 | ||||
Resistance 3 (R3) | 26.00 | 25.42 | 25.61 | ||
Resistance 2 (R2) | 25.42 | 24.93 | 25.39 | 25.50 | |
Resistance 1 (R1) | 24.71 | 24.63 | 24.42 | 24.65 | 25.40 |
Pivot Point | 24.13 | 24.13 | 23.99 | 24.10 | 24.13 |
Support 1 (S1) | 23.42 | 23.64 | 23.13 | 23.36 | 22.60 |
Support 2 (S2) | 22.84 | 23.34 | 22.81 | 22.50 | |
Support 3 (S3) | 22.13 | 22.84 | 22.39 | ||
Support 4 (S4) | 22.07 |